文献速递药物不良反应与药物警戒

组胺与恶心呕吐机制:赛克利嗪止吐药理的不确定性解读

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine.
PubMed 文献 · Br J Clin Pharmacol · 2026-09-14

赛克利嗪是注册用于晕动病、术后恶心呕吐(PONV)及「已知原因呕吐」的短效药物,但其止吐机制理解不足。本文综述已发表药理学研究,结合恶心呕吐已知机制进行解读,指出赛克利嗪拮抗人H1受体,治疗剂量仅弱拮抗毒蕈碱乙酰胆碱受体,对PONV、妊娠及姑息治疗中呕吐的机制尚不明确。

要点

  • 赛克利嗪拮抗人H1受体,治疗剂量仅弱拮抗毒蕈碱乙酰胆碱受体。
  • 晕动病改善与H1拮抗作用于前庭系统及脑干核团有关。
  • 组胺在PONV、妊娠及姑息治疗呕吐中的作用机制尚不明确。

核心结论

  • 赛克利嗪的药理学及其止吐活性机制理解不足,需可检验的假设进行研究。

研究设计与样本

  • 综述已发表的赛克利嗪药理学临床前及临床研究,结合恶心呕吐已知机制进行解读。

主要发现

  • 赛克利嗪拮抗人H1受体,可能引起轻度嗜睡,治疗剂量仅弱拮抗毒蕈碱乙酰胆碱受体。
  • 晕动病通过前庭系统及脑干相关核团的H1拮抗改善。
  • 组胺在PONV中贡献机制不清,可能来自肥大细胞和嗜碱性粒细胞刺激/致敏腹部迷走传入神经,与其他物质协同致吐。
  • 妊娠期呕吐抑制机制不明,GDF15参与但组胺关系不清;姑息治疗呕吐原因复杂,使用赛克利嗪不基于机制理解。
  • 所有适应症中恶心是否与呕吐同等程度减轻尚不明确;无一致证据支持用于胃轻瘫或化放疗呕吐。

关键数值与推荐

  • 赛克利嗪注册用于预防晕动病、PONV及「已知原因呕吐」,后者未定义,可能包括妊娠和姑息治疗患者,历史上无大型对照试验接受。

临床怎么用

  • 临床使用赛克利嗪应认识其H1拮抗作用及弱抗胆碱能特性,对PONV、妊娠及姑息治疗呕吐机制不清。
  • 不应基于一致证据将赛克利嗪用于胃轻瘫或化放疗所致呕吐。
  • 需注意恶心与呕吐缓解程度可能不一致,评估疗效时应分别关注。

局限性

  • 赛克利嗪药理学及止吐机制理解不足,需提出可检验假设进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cyclizine is a long-established, short-acting drug, registered for preventing motion sickness, post-operative nausea and vomiting (PONV) and 'vomiting of known cause'. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials. Cyclizine is often described as an 'antihistamine' and sometimes 'anticholinergic', without citing primary literature. Mechanisms of antiemetic activity are poorly understood. We reviewed the published pharmacology of cyclizine with the aim of understanding its mechanism of antiemetic activity. Preclinical/clinical studies were examined and findings interpreted with reference to known mechanisms of nausea and vomiting. Cyclizine antagonizes human H1 receptors and may cause mild drowsiness. Selectivity of action is unclear; therapeutic doses only weakly antagonize muscarinic ACh receptor(s). Motion sickness is ameliorated by H1 antagonism within the vestibular system and associated brainstem nuclei. Mechanisms by which histamine may contribute to PONV are unclear. Perhaps histamine from mast cells and basophils stimulate/sensitize abdominal vagal afferent nerves, synergising with other substances to cause vomiting. Any inhibition of vomiting by cyclizine during pregnancy is not understood; GDF15 is implicated, but relationships with histamine are unclear. Causes of nausea/vomiting during palliative care can be complex, and cyclizine is used without understanding mechanisms. For all indications, it is unclear if nausea is reduced to the same degree as vomiting. There is no consistent evidence to support using cyclizine for vomiting during gastroparesis or chemoradiotherapy. The pharmacology of cyclizine and mechanisms of its antiemetic activity are poorly understood. Testable hypotheses are suggested.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sanger GJ, Andrews PLR. Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine. Br J Clin Pharmacol. 2026. PMID: 42733333. doi:10.1002/bcp.70807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。